KRRO
Neutral signalScored 2026-09-13 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Korro Bio, Inc.
- Nom
- Korro Bio, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $177.0M
- Employés
- 57
- PDG
- Ram Aiyar
- Site web
- https://www.korrobio.com
- Marché
- ALTAMRNANNXANROAURADBVT
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 5 802 titres (~62 916,89 $ US)
- Insiders
- Aiyar Ram
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$162,353
Avg sell (VWAP, 90d window) $12.34 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$99,436 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-08-04
- Last synced
-
2026-08-10 09:45:27
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-11 | Dolan Oliver | Sell · S · 10b5-1 | 5 | $13.72 | $69 | Form 4 |
| 2026-09-09 | Dolan Oliver | Sell · S · 10b5-1 | 6 | $13.60 | $82 | Form 4 |
| 2026-09-08 | Dolan Oliver | Sell · S · 10b5-1 | 7,347 | $13.51 | $99,286 | Form 4 |
| 2026-08-04 | Aiyar Ram | Sell · S | 5,802 | $10.84 | $62,917 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-09-13 Drivers: fundamentals. Moteurs : fondamentaux.
KRRO combines severely distressed fundamentals (persistent operating losses, rapid cash burn, no profitability path) with a weak catalytic signal: while the Q2 2026 earnings report highlights pipeline progress on…
The first sentence of the analysis written for KRRO on 2026-09-13 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Neutral signal
Drivers: fundamentals. Moteurs : fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 6.90 · operating margin -1366% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 33.0% | 100.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | -1366.4% | -4047.1% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | -1299.5% | -3890.1% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | -1366.4% | -4047.1% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | -1824.5% | -3674.2% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | -1834.5% | -3680.4% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | -1834.5% | -3680.4% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | -1834.5% | -3680.4% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 6.901 | 8.792 | 8.866 | 6.561 | 11.790 | |
| Quick Ratio | 6.901 | 8.792 | 8.866 | 6.561 | 11.790 | |
| Solvency Ratio | -1.820 | -1.216 | -1.498 | -0.321 | -0.373 | |
| Cash Ratio | 1.828 | 3.719 | 8.528 | 4.245 | 6.968 | |
| Price To Earnings Ratio | -0.642 | -4.063 | -0.926 | -0.846 | -51.923 | |
| Price To Earnings Growth Ratio | -0.019 | 0.049 | 0.012 | -0.000 | 0.590 | |
| Forward Price To Earnings Growth Ratio | -0.019 | 0.049 | 0.012 | -0.000 | 0.590 | |
| Price To Earnings Diluted Ratio | -0.642 | -4.063 | -0.926 | -0.846 | -51.923 | |
| Price To Earnings Diluted Growth Ratio | -0.019 | 0.049 | 0.012 | -0.000 | 0.590 | |
| Price To Book Ratio | 1.463 | 2.117 | 0.442 | -0.496 | 8.719 | |
| Price To Sales Ratio | 11.774 | 149.540 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -0.952 | -4.355 | -1.000 | -0.834 | -31.216 | |
| Price To Operating Cash Flow Ratio | -0.958 | -5.653 | -1.117 | -0.915 | -35.541 | |
| Debt To Assets Ratio | 0.383 | 0.198 | 0.150 | 2.265 | 0.246 | |
| Debt To Equity Ratio | 0.845 | 0.279 | 0.195 | -1.686 | 0.349 | |
| Debt To Capital Ratio | 0.458 | 0.218 | 0.163 | 2.457 | 0.258 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 2.528 | 0.098 | |
| Financial Leverage Ratio | 2.207 | 1.410 | 1.305 | -0.745 | 1.417 | |
| Working Capital Turnover Ratio | 0.068 | 0.017 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -6.581 | -4.016 | -3.453 | -6.165 | -2.808 | |
| Operating Cash Flow Sales Ratio | -12.291 | -26.453 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.007 | 1.298 | 1.116 | 1.097 | 1.139 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | -18.591 | -13.140 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | -499.983 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | -18.365 | -12.440 | |
| Operating Cash Flow Coverage Ratio | -1.807 | -1.342 | -2.026 | -0.321 | -0.704 | |
| Capital Expenditure Coverage Ratio | -151.662 | -3.356 | -8.586 | -10.293 | -7.217 | |
| Dividend Paid And Capex Coverage Ratio | -151.662 | -3.356 | -8.586 | -10.293 | -7.217 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -1.167 | -3.721 | 0.715 | -3.171 | -32.645 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 33.0% | ▼-67.0% | ▲6.4% |
| Ebit Margin | -1366.4% | ▲2680.7% | ▼-283.7% |
| Ebitda Margin | -1299.5% | ▲2590.7% | ▼-261.6% |
| Operating Profit Margin | -1366.4% | ▲2680.7% | ▼-283.7% |
| Pretax Profit Margin | -1824.5% | ▲1849.6% | ▼-724.8% |
| Continuous Operations Profit Margin | -1834.5% | ▲1845.9% | ▼-731.5% |
| Net Profit Margin | -1834.5% | ▲1845.9% | ▼-731.5% |
| Bottom Line Profit Margin | -1834.5% | ▲1845.9% | ▼-731.5% |
| Current Ratio | 6.901 | ▼-1.892 | ▼-1.681 |
| Quick Ratio | 6.901 | ▼-1.892 | ▼-1.681 |
| Solvency Ratio | -1.820 | ▼-0.605 | ▼-0.774 |
| Cash Ratio | 1.828 | ▼-1.891 | ▼-3.229 |
| Price To Earnings Ratio | -0.642 | ▲3.421 | ▲11.038 |
| Price To Earnings Growth Ratio | -0.019 | ▼-0.069 | ▼-0.146 |
| Forward Price To Earnings Growth Ratio | -0.019 | ▼-0.069 | ▼-0.146 |
| Price To Earnings Diluted Ratio | -0.642 | ▲3.421 | ▲11.038 |
| Price To Earnings Diluted Growth Ratio | -0.019 | ▼-0.069 | ▼-0.146 |
| Price To Book Ratio | 1.463 | ▼-0.654 | ▼-0.986 |
| Price To Sales Ratio | 11.774 | ▼-137.767 | ▼-20.489 |
| Price To Free Cash Flow Ratio | -0.952 | ▲3.404 | ▲6.720 |
| Price To Operating Cash Flow Ratio | -0.958 | ▲4.695 | ▲7.879 |
| Debt To Assets Ratio | 0.383 | ▲0.185 | ▼-0.265 |
| Debt To Equity Ratio | 0.845 | ▲0.566 | ▲0.849 |
| Debt To Capital Ratio | 0.458 | ▲0.240 | ▼-0.253 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.525 |
| Financial Leverage Ratio | 2.207 | ▲0.796 | ▲1.088 |
| Working Capital Turnover Ratio | 0.068 | ▲0.051 | ▲0.051 |
| Operating Cash Flow Ratio | -6.581 | ▼-2.566 | ▼-1.976 |
| Operating Cash Flow Sales Ratio | -12.290 | ▲14.162 | ▼-4.542 |
| Free Cash Flow Operating Cash Flow Ratio | 1.007 | ▼-0.291 | ▼-0.125 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▲6.346 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲99.997 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲6.161 |
| Operating Cash Flow Coverage Ratio | -1.807 | ▼-0.465 | ▼-0.567 |
| Capital Expenditure Coverage Ratio | -151.662 | ▼-148.306 | ▼-115.439 |
| Dividend Paid And Capex Coverage Ratio | -151.662 | ▼-148.306 | ▼-115.439 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -1.167 | ▲2.554 | ▲6.831 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $75.3M | $339.6M | $75.1M | $49.1M | $1.14B | |
| Enterprise value | $96.9M | $328.7M | -$57.8M | $179.1M | $1.11B | |
| EV / Sales | 15.16x | 144.75x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -1.23x | -5.47x | 0.86x | -3.34x | -34.48x | |
| EV / Free cash flow | -1.23x | -4.22x | 0.77x | -3.04x | -30.28x | |
| EV / EBITDA | -1.17x | -3.72x | 0.71x | -3.17x | -32.65x | |
| Net debt / EBITDA | -0.26x | 0.12x | 1.64x | -2.30x | 1.00x | |
| Current ratio | 6.90x | 8.79x | 8.87x | 6.56x | 11.79x | |
| Income quality | 0.67x | 0.72x | 0.83x | 0.92x | 1.46x | |
| Graham net-net | $1 | $7 | $75 | -$459 | $17 | |
| Tax burden | 100.5% | 100.2% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 133.5% | 90.8% | 96.0% | 98.3% | 61.9% | |
| Working capital | $70.4M | $116.6M | $153.2M | $48.4M | $123.3M | |
| Invested capital | $86.7M | $168.1M | $196.1M | $60.3M | $160.2M | |
| Return on assets | -103.3% | -36.9% | -36.6% | -78.7% | -11.8% | |
| Operating ROA | -51.4% | -41.0% | -57.2% | -45.5% | -15.8% | |
| Return on tangible assets | -103.3% | -36.9% | -36.6% | -78.7% | -11.8% | |
| Return on equity | -228.0% | -52.1% | -47.8% | 58.6% | -16.8% | |
| Return on invested capital | -83.8% | -43.2% | -41.4% | -86.8% | -20.1% | |
| Return on capital employed | -86.0% | -43.5% | -41.8% | -90.7% | -20.4% | |
| Earnings yield | -155.8% | -24.6% | -108.0% | -118.2% | -1.9% | |
| Free cash flow yield | -105.1% | -23.0% | -100.0% | -119.9% | -3.2% | |
| Capex / Op. cash flow | -0.7% | -29.8% | -11.6% | -9.7% | -13.9% | |
| Capex / Depreciation | 13.7% | 502.2% | 215.9% | 207.6% | 278.8% | |
| Capex / Sales | 8.1% | 788.3% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 440.5% | 1345.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 1025.9% | 2802.1% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 119.8% | 196.5% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 55d | 273d | 0d | 0d | 0d | |
| Days payables outstanding | 141d | 0d | 0d | 0d | 0d | |
| Operating cycle | 55d | 273d | 0d | 0d | 0d | |
| Cash conversion cycle | -85d | 273d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-77.8%EV / Sales ▼-89.5%EV / EBITDA ▲+68.6%EV / Op. cash flow ▲+4.238Earnings yield ▼-1.312
Profitability
Return on equity ▼-1.759Return on assets ▼-0.664Return on invested capital ▼-0.405Return on capital employed ▼-0.425Operating ROA ▼-0.104Income quality ▼-0.049Tax burden ▲+0.004
Efficiency
Days sales outstanding ▼-217.252Days payables outstanding n/aOperating cycle ▼-217.252Cash conversion cycle ▼-358.050Capex / Sales ▼-7.802R&D / Sales ▼-17.762
Balance-sheet strength
Current ratio ▼-1.892Net debt / EBITDA ▼-0.384Working capital ▼-46137000.000Invested capital ▼-81461000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-93.4%EV / Sales n/aEV / EBITDA ▲+96.4%EV / Op. cash flow ▲+33.247Earnings yield ▼-1.539
Profitability
Return on equity ▼-2.112Return on assets ▼-0.915Return on invested capital ▼-0.637Return on capital employed ▼-0.656Operating ROA ▼-0.356Income quality ▼-0.792Tax burden ▲+0.005
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-4.889Net debt / EBITDA ▼-1.265Working capital ▼-52884000.000Invested capital ▼-73534000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Recent news
- 2026-08-06 Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical trial in second half of 2026 Received Orphan Drug Designation from the European Medicines Agency (EMA) for KRRO-121 for patients with urea cycle disorders (UCDs) Nominated KRRO-111 as development candidate for the treatment of Alpha-1 Antitrypsin Deficiency (AATD); potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting both the liver and lungs Ended second quarter 2026 with $137.9 million in cash, cash equivalents and marketable securities; provides sufficient resources to achieve value inflection points for multiple RNA editing programs including clinical data for KRRO-121 and KRRO-111; cash runway into the second half of 2028 CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today reported results for the second quarter ended June 30, 2026, and provided a corporate update.
- 2026-07-22 Reviewing Korro Bio (NASDAQ:KRRO) and Enlivex Therapeutics (NASDAQ:ENLV) Enlivex Therapeutics (NASDAQ: ENLV - Get Free Report) and Korro Bio (NASDAQ: KRRO - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability. Institutional and Insider Ownership 1.0% of Enlivex
- 2026-07-10 Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., July 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of non-statutory stock options to seven newly hired employees.
- 2026-07-08 Korro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock? Korro Bio, Inc. (KRRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 2026-06-19 Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock? Korro Bio, Inc. (KRRO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 2026-05-27 Korro to Present at the 2026 Jefferies Global Healthcare Conference CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D.
- 2026-05-19 Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD) Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting both the liver and lungs Demonstrated >90% editing of SERPINA1 transcript in vivo translating into ~90% repaired functional alpha-1 antitrypsin (AAT) protein in plasma in a mouse model of AATD Demonstrated a near elimination of active Z-protein production while showing progressive clearance of pre-existing aggregates in a mouse model of AATD Pre-clinical data highlighted the possibility of repeat dose therapy to achieve the functional equivalent of a DNA modification without altering the genome CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the addition of KRRO-111 for the potential treatment of AATD to its pipeline of therapeutic programs in development.
- 2026-05-15 Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of a non-statutory stock option to one newly hired employee.